These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 30146960

  • 1. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
    Lum K, Bhatti T, Holland S, Guthrie M, Sassman S.
    J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH, Outterson K.
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr JF.
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [Abstract] [Full Text] [Related]

  • 7. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T, Lum K, Holland S, Sassman S, Findlay D, Outterson K.
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [Abstract] [Full Text] [Related]

  • 8. Resistance diagnosis and the changing economics of antibiotic discovery.
    McAdams D.
    Ann N Y Acad Sci; 2017 Jan; 1388(1):18-25. PubMed ID: 28072904
    [Abstract] [Full Text] [Related]

  • 9. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH.
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [Abstract] [Full Text] [Related]

  • 10. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE, Morel CM.
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [Abstract] [Full Text] [Related]

  • 11. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development.
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [Abstract] [Full Text] [Related]

  • 12. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM, Mossialos E.
    Global Health; 2013 Nov 07; 9():58. PubMed ID: 24199835
    [Abstract] [Full Text] [Related]

  • 13. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM, Mossialos E.
    Soc Sci Med; 2016 Feb 07; 151():167-72. PubMed ID: 26808335
    [Abstract] [Full Text] [Related]

  • 14. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E, Ciabuschi F, Leach R, Morel CM, Waluszewski A.
    Am J Law Med; 2016 May 07; 42(2-3):451-486. PubMed ID: 29086643
    [Abstract] [Full Text] [Related]

  • 15. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway.
    Årdal C, Johnsen J, Johansen K.
    J Law Med Ethics; 2018 Jun 07; 46(1_suppl):43-49. PubMed ID: 30146956
    [Abstract] [Full Text] [Related]

  • 16. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.
    Garrison LP, Towse A.
    J Pers Med; 2017 Sep 04; 7(3):. PubMed ID: 28869571
    [Abstract] [Full Text] [Related]

  • 17. Implementing Medicare prospective pricing by diagnosis related groups.
    Crawford M.
    Ala J Med Sci; 1984 Jan 04; 21(1):96-100. PubMed ID: 6422785
    [No Abstract] [Full Text] [Related]

  • 18. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH, Mohr JF.
    Expert Rev Anti Infect Ther; 2017 May 04; 15(5):425-433. PubMed ID: 28306360
    [Abstract] [Full Text] [Related]

  • 19. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C, Lacotte Y, Edwards S, Ploy MC, On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai.
    Antibiotics (Basel); 2021 Jun 21; 10(6):. PubMed ID: 34205554
    [Abstract] [Full Text] [Related]

  • 20. The economics of resistant pathogens and antibiotic innovation.
    McKellar MR, Chernew ME, Fendrick AM.
    Am J Manag Care; 2014 Mar 21; 20(3):193-7. PubMed ID: 24884749
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.